Back to Search
Start Over
Buprenorphine Induction in Persons With Opioid Use Disorder Hospitalized with Acute Hepatitis A.
- Source :
-
Journal of addiction medicine [J Addict Med] 2021 May-Jun 01; Vol. 15 (3), pp. 187-190. - Publication Year :
- 2021
-
Abstract
- Background: It is not known whether buprenorphine/naloxone (bup/nx) can be safely initiated in hospitalized patients with acute hepatitis A infection. We assessed liver function and tolerability of bup/nx induction in patients with acute Hepatitis A Virus (HAV).<br />Methods: Retrospective review of patients (Nā=ā31) admitted to a tertiary care facility for acute HAV who were evaluated by an addiction medicine consultant.<br />Results: No significant difference was seen in aspartate aminotransferase, alanine aminotransferase, total bilirubin, or INR trends in patients receiving bup/nx during hospitalization versus those not receiving bup/nx. Nausea was the most common reported symptom in patients receiving bup/nx.<br />Discussion and Conclusions: With careful monitoring and induction dose adjustment, bup/nx can be administered to patients with acute HAV without hepatic encephalopathy. Similarly, patients on bup/nx before hospitalization should not have this medication held in the setting of acute HAV.<br />Scientific Significance: This strategy may engage patients with acute HAV in treatment of OUD earlier and minimize disruptions in treatment.<br />Competing Interests: The authors have no conflicts of interests to disclose.<br /> (Copyright © 2020 American Society of Addiction Medicine.)
Details
- Language :
- English
- ISSN :
- 1935-3227
- Volume :
- 15
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Journal of addiction medicine
- Publication Type :
- Academic Journal
- Accession number :
- 32909986
- Full Text :
- https://doi.org/10.1097/ADM.0000000000000730